The biotech company Moderna (Nasdaq: MRNA) generated billions of dollars in earnings from its coronavirus vaccine, but sales of the vaccine — its only product — are on the decline. Still, the company’s best days may be ahead of it. Moderna has a full pipeline of programs, with many in late-stage development. In fact, the company aims to launch 15 […]
Sorry! An active online subscription is required to access this content.
Please login below or Subscribe today!